UniBio Intelligence Selected for Anthropic’s Rare Disease Research Program

BAR HARBOR, Maine, September 23, 2026 — UniBio Intelligence today announced that its RareDose project has been selected for Anthropic’s AI for Science rare disease research program. The award provides Claude usage credits over a six-month project period to support research connecting source-traceable evidence with quantitative pharmacology models for rare diseases.

According to Anthropic’s selection notification, the program received more than 750 applications and selected 100 projects covering more than 75 named rare conditions. The cohort spans mechanism discovery, variant interpretation, therapeutic design, trial readiness, and evaluations of AI reasoning in rare disease research.

RareDose will initially focus on complement-mediated rare disease, beginning with atypical hemolytic uremic syndrome (aHUS). The project aims to assemble published evidence into reproducible models of drug exposure and biological response, linking modeling assumptions to their sources and documenting uncertainty and gaps in the evidence.

UniBio Intelligence will use Claude to assist with evidence curation, model implementation, and documentation, alongside numerical simulation and expert review. The research will evaluate whether this approach can make fragmented evidence easier to inspect, test, and reuse in pharmacology modeling and future studies.

Anthropic’s program supports scientists and early-stage biotechnology companies exploring applications of AI in rare disease research and development. UniBio Intelligence plans to share the RareDose approach and evaluation framework as the project progresses.